[{"id":"089a9873-0dbf-4d04-a926-ae092495901f","acronym":"ComboMATCH","url":"https://clinicaltrials.gov/study/NCT05554380","created_at":"2022-09-26T14:56:10.419Z","updated_at":"2025-02-25T12:38:22.753Z","phase":"Phase 2","brief_title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554380 - ComboMATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT2","pipe":" | ","alterations":" AKT1 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-24"},{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"15959a9a-70ff-446f-ba15-1dcc1140abaf","acronym":"NRG-GY028","url":"https://clinicaltrials.gov/study/NCT05538897","created_at":"2022-09-14T18:56:09.184Z","updated_at":"2025-02-25T13:49:32.512Z","phase":"Phase 1/2","brief_title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","source_id_and_acronym":"NCT05538897 - NRG-GY028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1S1","pipe":"","alterations":" ","tags":["AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ipatasertib (RG7440) • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-20"},{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"696d727b-575b-4b42-9ab7-71058751cfe0","acronym":"NCI-2021-13902","url":"https://clinicaltrials.gov/study/NCT05172258","created_at":"2021-12-29T13:53:34.637Z","updated_at":"2025-02-25T16:32:39.281Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","source_id_and_acronym":"NCT05172258 - NCI-2021-13902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-07"},{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"acc6da2f-38b7-4ab4-ba2e-48ab70259f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532552","created_at":"2025-02-26T13:41:40.179Z","updated_at":"2025-02-26T13:41:40.179Z","phase":"Phase 2","brief_title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06532552","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 07/29/2024","start_date":" 07/29/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-11-20"},{"id":"23a26ba2-c7b3-4108-b7df-8c971e5ceef9","acronym":"DEL Biomarker","url":"https://clinicaltrials.gov/study/NCT06652152","created_at":"2025-02-26T12:22:45.189Z","updated_at":"2025-02-26T12:22:45.189Z","phase":"","brief_title":"Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma","source_id_and_acronym":"NCT06652152 - DEL Biomarker","lead_sponsor":"Ruijin Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-22"},{"id":"8cb4234f-c738-4083-b46f-8fc3430135ea","acronym":"ComPAKT","url":"https://clinicaltrials.gov/study/NCT02338622","created_at":"2021-01-17T17:26:12.811Z","updated_at":"2025-02-25T15:06:26.078Z","phase":"Phase 1","brief_title":"Trial of Olaparib in Combination with AZD5363 (ComPAKT)","source_id_and_acronym":"NCT02338622 - ComPAKT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" BRCA1 • BRCA2 • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2024-09-26"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"1c48e572-289e-4bd6-8e9e-55f35357c771","acronym":"SCALOP-2","url":"https://clinicaltrials.gov/study/NCT02024009","created_at":"2025-02-25T14:34:28.767Z","updated_at":"2025-02-25T14:34:28.767Z","phase":"Phase 1/2","brief_title":"Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2","source_id_and_acronym":"NCT02024009 - SCALOP-2","lead_sponsor":"University of Oxford","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • albumin-bound paclitaxel • Viracept (nelfinavir)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 06/23/2021","primary_completion_date":" 06/23/2021","study_txt":" Completion: 06/23/2021","study_completion_date":" 06/23/2021","last_update_posted":"2024-07-25"},{"id":"01bb6da0-1295-4869-97f4-aac2478019c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674683","created_at":"2021-01-19T20:45:32.528Z","updated_at":"2025-02-25T14:29:47.853Z","phase":"Phase 3","brief_title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","source_id_and_acronym":"NCT04674683","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • PD-L1 negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-06-24"},{"id":"12f81b1d-451f-4a1e-b774-333646268edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009992","created_at":"2024-06-15T04:08:56.168Z","updated_at":"2024-07-02T16:34:26.237Z","phase":"Phase 2","brief_title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","source_id_and_acronym":"NCT05009992","lead_sponsor":"University of California, San Francisco","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-06-13"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"7b8dfa1c-2da2-4d1b-8945-ea6ec1ea6662","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720260","created_at":"2023-02-09T15:00:11.511Z","updated_at":"2024-07-02T16:34:27.630Z","phase":"Phase 2","brief_title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","source_id_and_acronym":"NCT05720260","lead_sponsor":"National Taiwan University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • fulvestrant • Truqap (capivasertib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"64151ea0-5e4f-4551-a71f-36af8cc5de9e","acronym":"IPATential150","url":"https://clinicaltrials.gov/study/NCT03072238","created_at":"2021-01-17T17:45:45.867Z","updated_at":"2024-07-02T16:34:37.052Z","phase":"Phase 3","brief_title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03072238 - IPATential150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • ipatasertib (RG7440) • prednisone • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 1101","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/16/2020","primary_completion_date":" 03/16/2020","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2024-06-07"},{"id":"b5216033-99a5-4f51-828d-87fa62fb0d17","acronym":"CAPItello-292","url":"https://clinicaltrials.gov/study/NCT04862663","created_at":"2021-04-28T13:53:54.000Z","updated_at":"2024-07-02T16:34:37.553Z","phase":"Phase 3","brief_title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","source_id_and_acronym":"NCT04862663 - CAPItello-292","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 08/14/2029","study_completion_date":" 08/14/2029","last_update_posted":"2024-06-06"},{"id":"ded04c2b-2ead-4cff-9660-0481bc077bfe","acronym":"MORPHEUS","url":"https://clinicaltrials.gov/study/NCT03280563","created_at":"2021-01-18T16:11:59.285Z","updated_at":"2024-07-02T16:34:37.795Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT03280563 - MORPHEUS","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/26/2017","start_date":" 12/26/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"b30a8bca-2be6-49b4-90f3-03ff7a00b1ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586270","created_at":"2021-01-18T21:52:48.356Z","updated_at":"2024-07-02T16:34:37.959Z","phase":"Phase 1","brief_title":"A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT04586270","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • KRAS • PTEN • NF1","pipe":" | ","alterations":" KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative","tags":["HER-2 • KRAS • PTEN • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAS0612"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-05"},{"id":"1315f5e9-3b04-4aab-a843-bdf4b3d84f6e","acronym":"SNARE","url":"https://clinicaltrials.gov/study/NCT05593497","created_at":"2022-10-25T13:56:29.819Z","updated_at":"2024-07-02T16:34:59.265Z","phase":"Phase 2","brief_title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","source_id_and_acronym":"NCT05593497 - SNARE","lead_sponsor":"VA Office of Research and Development","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-06-04"},{"id":"846b7653-3cb1-438a-96c1-7360840819e9","acronym":"Amelia-1","url":"https://clinicaltrials.gov/study/NCT05455619","created_at":"2022-07-13T12:56:21.512Z","updated_at":"2024-07-02T16:35:02.003Z","phase":"Phase 1/2","brief_title":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer","source_id_and_acronym":"NCT05455619 - Amelia-1","lead_sponsor":"SynDevRx, Inc.","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • evexomostat (SDX-7320)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-22"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"}]